Cyclacel Group plc
("Cyclacel"), the cell cycle-focused biopharmaceutical company, announced today
that CYC116 an Aurora kinase inhibitor, has entered IND-directed preclinical
development. CYC116 is a small molecule investigational drug which demonstrated
anticancer activity after oral administration in both hematological and solid
tumor models. The company plans to file an Investigational New Drug (IND)
application for CYC116 with the United States Food and Drug Administration in
2006.
